Related references
Note: Only part of the references are listed.NEDA status in highly active MS can be more easily obtained with autologous hematopoietic stem cell transplantation than other drugs
Maria Pia Sormani et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
NEDA status in highly active MS can be more easily obtained with autologous hematopoietic stem cell transplantation than other drugs
Maria Pia Sormani et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Autologous hematopoietic stem cell transplantation in multiple sclerosis A meta-analysis
Maria Pia Sormani et al.
NEUROLOGY (2017)
High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study
Simona Malucchi et al.
NEUROLOGY AND THERAPY (2017)
Rituximab versus Fingolimod after Natalizumab in Multiple Sclerosis Patients
Peter Alping et al.
ANNALS OF NEUROLOGY (2016)
Disease activity return after natalizumab cessation in multiple sclerosis
Maria Rasenack et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2016)
Autologous hematopoietic stem cell transplantation in multiple sclerosis: 20 years of experience
Daniela Curr et al.
NEUROLOGICAL SCIENCES (2016)
Disease activity return after natalizumab cessation in multiple sclerosis
Maria Rasenack et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2016)
Switching from natalizumab to fingolimod A randomized, placebo-controlled study in RRMS
Ludwig Kappos et al.
NEUROLOGY (2015)
Is it time to target no evident disease activity (NEDA) in multiple sclerosis?
Gavin Giovannoni et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2015)
T cell repertoire following autologous stem cell transplantation for multiple sclerosis
Paolo A. Muraro et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients
Per Soelberg Sorensen et al.
JOURNAL OF NEUROLOGY (2014)
MS disease activity in RESTORE A randomized 24-week natalizumab treatment interruption study
Robert J. Fox et al.
NEUROLOGY (2014)
Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis
Joachim Havla et al.
JOURNAL OF NEUROLOGY (2013)
Natalizumab Therapy for Multiple Sclerosis
Tobias Derfuss et al.
SEMINARS IN NEUROLOGY (2013)
Bridging, switching or drug holidays - how to treat a patient who stops natalizumab?
Joachim Havla et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2013)
Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis
P. W. O'Connor et al.
NEUROLOGY (2011)
Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases
Dominique Farge et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Immune re-education following autologous hematopoietic stem cell transplantation
Sofia Abrahamsson et al.
AUTOIMMUNITY (2008)
Share Paper
